Neoadjuvant Phase II Trial of Paclitaxel in Combination With BKM120 in Endocrine Resistant Clinical Stage II or III Estrogen Receptor-Positive and HER2 Negative Breast Cancer
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 24 Dec 2014
Price : $35 *
At a glance
- Drugs Buparlisib (Primary) ; Paclitaxel
- Indications Breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 24 Nov 2014 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 03 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.